Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Datebook: What’s On The Agenda This Week

This article was originally published in The Pink Sheet Daily

Executive Summary

Events on tap include release of GWU’s obesity drugs outcomes report, developed at FDA’s request, and the sure-to-be contentious Forest shareholders meeting.


Related Content

Merck Drops Zocor Combo, But Keeps Going With Tredaptive
Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave
Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly
Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts